AbbVie Inc.

06/11/2021 | Press release | Distributed by Public on 06/10/2021 23:08

New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three[...]